ACTON, Mass. — Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand, has appointed Ashley McEvoy as its new president and chief executive officer, effective immediately. The announcement comes as the company anticipates exceeding its first-quarter revenue guidance and plans to raise its full-year 2025 outlook.
McEvoy, who also joins Insulet’s board of directors, succeeds Jim Hollingshead, whose departure was mutually agreed upon with the board. Hollingshead, who has served as CEO since stepping in from the board, will remain in a consulting role to ensure a smooth leadership transition.
“Under Jim’s leadership, Insulet has experienced a remarkable period of growth and innovation, including the successful launch of Omnipod 5, which has achieved market leadership in type 1 diabetes across the U.S. and Europe and broke new ground in automated insulin delivery for type 2 diabetes,” said Timothy Scannell, chairman of Insulet’s board of directors. “We thank Jim for his contributions and leadership during this transformative time for the company.”
McEvoy brings nearly 30 years of healthcare leadership experience, including her recent role as executive vice president and worldwide chairman of Johnson & Johnson’s MedTech division. She also has significant diabetes sector experience from her time leading Johnson & Johnson’s Vision and Diabetes Care businesses.
“Our board conducted a comprehensive search to find a dynamic leader who could advance Insulet’s mission and growth trajectory,” Scannell said. “Ashley’s extensive MedTech expertise, combined with her consumer health insights and proven track record of driving innovation and market expansion, made her the ideal choice to lead Insulet into its next chapter.”
In her first statement as CEO, McEvoy praised Insulet’s position as a leader in diabetes care, citing its strong pharmacy channel access, manufacturing capabilities, and loyal customer base. “Insulet has massive, untapped growth potential,” McEvoy said. “At this pivotal moment in the company’s evolution, there is a unique opportunity to further global expansion, enhance innovation, and reimagine the experience of people living with diabetes. I am honored to lead this talented team and continue to revolutionize diabetes care.”
Hollingshead expressed pride in his time at Insulet, reflecting on the company’s strides in advancing diabetes treatment and reaching hundreds of thousands of customers worldwide. “It has been a privilege to serve as Insulet’s CEO,” he said. “I look forward to seeing the company achieve even greater success in the years ahead.”
The leadership transition positions Insulet for continued growth as it scales its flagship Omnipod platform and expands into new markets. The company’s upcoming revised financial guidance reflects its confidence in its business momentum for 2025.
